Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,122 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,536 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (884)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07344220 | Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate(DZ-002-201) | enrolling by invitation | Phase 2 | 39 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04291755 | Development and Analysis of a Stool Bank for Cancer Patients | enrolling by invitation | — | 100 | Persephone BiosciencesINDUSTRY | 1 | Sep 18, 2026 |
| clinicaltrials |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06157671 | The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma | enrolling by invitation | — | 1,000 | Adenocyte, LLCINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06276764 | The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas) | enrolling by invitation | — | 500 | Adenocyte, LLCINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07703735 | Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma(HCC) | enrolling by invitation | — | 371 | Seoung Hoon KimOTHER_GOV | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07139951 | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence | enrolling by invitation | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02600949 | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | enrolling by invitation | Phase 1 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07218003 | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | enrolling by invitation | Phase 1 | 149 | Rondo TherapeuticsINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06744595 | Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic Cancer | enrolling by invitation | N/A | 50 | Mayo ClinicOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06885424 | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products(DESCENT-1) | enrolling by invitation | — | 400 | A2 Biotherapeutics Inc.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT06862479 | Luso-Cor Stent Compared to Other Endoscopic Techniques for Management of Fistulas and Anastomotic Dehiscences(ES-LCCE-UDFM)(ES-LCCE-UDFM) | enrolling by invitation | — | 180 | Unidade Local de Saúde Santa MariaOTHER_GOV | 1 | May 6, 2026 | clinicaltrials |
| NCT07212491 | Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma | enrolling by invitation | — | 450 | Mayo ClinicOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07567716 | Infiltration Pattern of Locally Advanced ESCC | enrolling by invitation | — | 30 | Shanghai Chest HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06381882 | The Role of the Human Microbiome in Patients After Pancreatic Resection.(MiPac) | enrolling by invitation | — | 200 | St. Antonius HospitalOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07298577 | Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer(STOPHCC-GAAD) | enrolling by invitation | N/A | 2,100 | Siriraj HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07533825 | Laparoscopic Staging for Stage III Gastric Cancer(CGCA202501) | enrolling by invitation | N/A | 968 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06474091 | Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO) | enrolling by invitation | — | 100 | Mayo ClinicOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT00587314 | The Effect of Ablation Therapy on Barrett's Esophagus(ablation IN BE) | enrolling by invitation | — | 600 | Mayo ClinicOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06624189 | Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis | enrolling by invitation | — | 1,300 | NYU Langone HealthOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05441475 | A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients | enrolling by invitation | Phase 2 | 118 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06061328 | Project OASIS: Optimizing Approaches to Select Implementation Strategies(OASIS) | enrolling by invitation | N/A | 8,020 | VA Office of Research and DevelopmentFED | 1 | Feb 4, 2026 | clinicaltrials |
| NCT02081755 | Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer | enrolling by invitation | Phase 4 | 336 | Baylor Research InstituteOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07356466 | Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(FUGES032) | enrolling by invitation | Early Phase 1 | 100 | Fujian Medical UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07334587 | Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma | enrolling by invitation | N/A | 248 | Allama Iqbal Medical CollegeOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07312578 | Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma | enrolling by invitation | Phase 2 | 48 | Peking UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07290764 | Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy | enrolling by invitation | — | 729 | Fujian Provincial HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07241676 | Early Recurrence After Surgery for Pancreatic Cancer(POCEMON BLUE) | enrolling by invitation | — | 500 | Azienda Ospedaliera di PadovaOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04539717 | FAST (Focused Abbreviated Screening Technique)-MRI Study | enrolling by invitation | — | 820 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT06882876 | JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study | enrolling by invitation | Phase 1 | 20 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07052448 | The Efficacy of Sequential RT After Triple Therapy for uHCC | enrolling by invitation | — | 35 | Fujian Provincial HospitalOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07046832 | Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy | enrolling by invitation | N/A | 104 | MediView XR, Inc.INDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07047937 | Explainable Machine Learning for Predicting Early Gastric Cancer | enrolling by invitation | — | 10 | Wenzhou Central HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07016737 | Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy(ESO-Nanjing12) | enrolling by invitation | Phase 3 | 79 | Ye jinjunOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06990178 | Adaptive Neoadjuvant Therapy for Esophageal Cancer | enrolling by invitation | N/A | 43 | Cancer Hospital Chinese Academy of Medical Science, Shenzhen CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06967662 | Selective Plasma Adsorption of Extracellular DNA in Prevention of Intraoperative Metastasis in Pancreatic Cancer (Pilot Study)(INTRACOR_pilot) | enrolling by invitation | N/A | 28 | Ilyinskaya Hospital, JSCOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06963060 | Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)(GALENT-BT) | enrolling by invitation | Phase 2 | 44 | Wei GongOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06931808 | Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer | enrolling by invitation | Phase 4 | 20 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06923020 | Association of Nutritional Status With Immune Checkpoint Inhibitor Efficacy in Metastatic Metastatic Esophagogastric Cancer. | enrolling by invitation | — | 200 | Yongxu JiaOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06715501 | Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | enrolling by invitation | N/A | 20 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 25, 2025 | clinicaltrials |
| NCT06863831 | A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC | enrolling by invitation | N/A | 536 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | enrolling by invitation | Phase 1 / Phase 2 | 20 | Siriraj HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06774170 | Structured Follow-up Intervention on Glucose Status After Pancreatic Cancer Surgery(FiGluR) | enrolling by invitation | N/A | 40 | Dokuz Eylul UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06712017 | Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China | enrolling by invitation | — | 100 | GrandPharma (China) Co., Ltd.INDUSTRY | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06647264 | A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery | enrolling by invitation | — | 1,500 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04195503 | Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma | enrolling by invitation | N/A | 10 | University Health Network, TorontoOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04793633 | Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic Cancer | enrolling by invitation | — | 500 | Adenocyte, LLCINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06303583 | Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma(CRIS) | enrolling by invitation | Phase 1 / Phase 2 | 30 | Qiu GuoqinOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06076252 | Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma | enrolling by invitation | N/A | 150 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06048926 | Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma | enrolling by invitation | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials